MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571347 | Name: Atrasentan free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Atrasentan, also known as ABT-627, is a orally available ETA receptor antagonist with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.

Chemical Structure

Atrasentan free base
Atrasentan free base
CAS#173937-91-2 (free base)

Theoretical Analysis

MedKoo Cat#: 571347

Name: Atrasentan free base

CAS#: 173937-91-2 (free base)

Chemical Formula: C29H38N2O6

Exact Mass: 510.2730

Molecular Weight: 510.63

Elemental Analysis: C, 68.21; H, 7.50; N, 5.49; O, 18.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
195733-43-8 (HCl) 173937-91-2 (free base) 178738-96-0 (sodium) 195704-72-4 (free base)
Synonym
Atrasentan Hydrochloride; Atrasentan HCl; A 147627; A-147627; A147627
IUPAC/Chemical Name
3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-
InChi Key
MOTJMGVDPWRKOC-QPVYNBJUSA-N
InChi Code
InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
SMILES Code
O=C([C@H]1[C@H](C2=CC=C(OC)C=C2)N(CC(N(CCCC)CCCC)=O)C[C@@H]1C3=CC=C(OCO4)C4=C3)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 510.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, Januzzi JL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Increase in BNP in Response to Endothelin- Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 Jul;10(7):498-507. doi: 10.1016/j.jchf.2022.03.004. Epub 2022 May 4. PMID: 35772861. 2: Jackson AM, Benson L, Savarese G, Hage C, Jhund PS, Petrie MC, Dahlström U, McMurray JJV, Lund LH. Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. JACC Heart Fail. 2022 Jun;10(6):380-392. doi: 10.1016/j.jchf.2022.04.006. PMID: 35654522. 3: Chavez E, Rodriguez J, Drexler Y, Fornoni A. Novel Therapies for Alport Syndrome. Front Med (Lausanne). 2022 Apr 25;9:848389. doi: 10.3389/fmed.2022.848389. PMID: 35547199; PMCID: PMC9081811. 4: Stuart DC Stuart, Peterson C, Hu C, Revelo MP, Huang Y, Kohan DE, Ramkumar N. Lack of renoprotective effects of targeting the endothelin A receptor and/or sodium glucose transporter 2 in a mouse model of type 2 diabetic kidney disease. Can J Physiol Pharmacol. 2022 May 7. doi: 10.1139/cjpp-2022-0082. Epub ahead of print. PMID: 35531905. 5: Hula N, Vu J, Quon A, Kirschenman R, Spaans F, Liu R, Cooke CM, Davidge ST. Sex-specific effects of prenatal hypoxia on the cardiac endothelin system in adult offspring. Am J Physiol Heart Circ Physiol. 2022 Mar 1;322(3):H442-H450. doi: 10.1152/ajpheart.00636.2021. Epub 2022 Feb 4. PMID: 35119336. 6: Culshaw G, Binnie D, Dhaun N, Hadoke P, Bailey M, Webb DJ. The acute pressure natriuresis response is suppressed by selective ETA receptor blockade. Clin Sci (Lond). 2021 Dec 17;136(1):15–28. doi: 10.1042/CS20210937. Epub ahead of print. PMID: 34918049; PMCID: PMC8734438. 7: Ahmad N, Veerapalli H, Lankala CR, Castaneda EE, Aziz A, Rockferry AG, Hamid P. Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review. Cureus. 2021 Nov 7;13(11):e19325. doi: 10.7759/cureus.19325. PMID: 34909290; PMCID: PMC8653857. 8: Ortiz A, Fernandez-Fernandez B. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2021 Dec 1;16(12):1775–8. doi: 10.2215/CJN.13601021. Epub ahead of print. PMID: 34853063; PMCID: PMC8729503. 9: Waijer SW, Gansevoort RT, Bakris GL, Correa-Rotter R, Hou FF, Kohan DE, Kitzman DW, Makino H, McMurray JJV, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 Dec 1;16(12):1824–32. doi: 10.2215/CJN.07340521. Epub ahead of print. PMID: 34853062; PMCID: PMC8729501. 10: Heerspink HJL, Xie D, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Perkovic V, Rossing P, Parving HH, de Zeeuw D; on behalf on the SONAR Investigators. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 Nov;32(11):2900-2911. doi: 10.1681/ASN.2021030391. Epub 2021 Sep 22. PMID: 34551995; PMCID: PMC8806086. 11: Bądzyńska B, Vaneckova I, Sadowski J, Hojná S, Kompanowska-Jezierska E. Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats. Eur J Pharmacol. 2021 Nov 5;910:174445. doi: 10.1016/j.ejphar.2021.174445. Epub 2021 Sep 4. PMID: 34492284. 12: Habib YH, Gowayed MA, Abdelhady SA, El-Deeb NM, Darwish IE, El-Mas MM. Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats. Naunyn Schmiedebergs Arch Pharmacol. 2021 Nov;394(11):2273-2287. doi: 10.1007/s00210-021-02146-7. Epub 2021 Sep 1. PMID: 34468816. 13: Khurana N, James S, Coughlan MT, MacIsaac RJ, Ekinci EI. Novel Therapies for Kidney Disease in People With Diabetes. J Clin Endocrinol Metab. 2022 Jan 1;107(1):e1-e24. doi: 10.1210/clinem/dgab639. PMID: 34460928. 14: Waijer SW, de Vries ST, Busch R, Xie D, Gansevoort RT, Hou FF, Górriz JL, Laverman GD, De Nicola L, Pascual J, Provenzano M, Pergola PE, Tang SCW, Wanner C, Zaoui P, Parving HH, de Zeeuw D, Heerspink HJL. Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Post Hoc Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 Nov;32(11):2731-2734. doi: 10.1681/ASN.2021040498. Epub 2021 Aug 20. PMID: 34417318; PMCID: PMC8806091. 15: Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Nov 1;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632. PMID: 34319398; PMCID: PMC8576587. 16: Rivera-Gonzalez O, Wilson NA, Coats LE, Taylor EB, Speed JS. Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice. Clin Sci (Lond). 2021 Jul 30;135(14):1773-1789. doi: 10.1042/CS20210549. PMID: 34278410; PMCID: PMC8650556. 17: Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, Murphy CL, Ford TJ, Sidik N, McEntegart MB, Lang NN, Jhund PS, Campbell RT, McMurray JJV, Petrie MC. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Oct 1;6(10):1130-1143. doi: 10.1001/jamacardio.2021.1825. PMID: 34160566; PMCID: PMC8223134. 18: Habib YH, Abdelhady SA, Gowayed MA, El-Deeb NM, Darwish IE, El-Mas MM. Prenatal endothelin or thromboxane receptor antagonism surpasses sympathoinhibition in improving cardiorenal malfunctions in preeclamptic rats. Toxicol Appl Pharmacol. 2021 Sep 1;426:115615. doi: 10.1016/j.taap.2021.115615. Epub 2021 Jun 6. PMID: 34102242. 19: Berillo O, Coelho SC, Mahjoub N, Offermanns S, Paradis P, Schiffrin EL. Aldosterone contributes to hypertension in male mice inducibly overexpressing human endothelin-1 in endothelium. J Hypertens. 2021 Sep 1;39(9):1908-1917. doi: 10.1097/HJH.0000000000002880. Erratum in: J Hypertens. 2021 Nov 1;39(11):2333. PMID: 34039912. 20: Smeijer JD, Kohan DE, Webb DJ, Dhaun N, Heerspink HJL. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):456-465. doi: 10.1097/MNH.0000000000000716. PMID: 33990507..